Related Experiment Video
Updated: Mar 26, 2026
06:47
A Murine Model of Vertical Sleeve Gastrectomy
Published on: December 18, 2017
11.9K
Severe Insulin Resistance Improves Immediately After Sleeve Gastrectomy
Rahul Sharma1, Chandra Hassan2, Joumana T Chaiban1
1Case Western Reserve University, Cleveland, OH, USA; St Vincent Charity Medical Center, Cleveland, OH, USA.
Journal of Investigative Medicine High Impact Case Reports
|January 21, 2016
Summary
Sleeve gastrectomy dramatically improved severe insulin resistance in an obese patient with type 2 diabetes. This bariatric surgery led to a significant reduction in insulin needs and improved HOMA-IR scores shortly after the procedure.
Area of Science:
- Metabolic Surgery
- Endocrinology
- Bariatric Surgery
Background:
- Obesity is linked to insulin resistance and adverse health outcomes.
- Bariatric surgery shows superior results for insulin resistance and glycemic control compared to medical therapy.
- Severe insulin resistance poses significant health challenges.
Purpose of the Study:
- To report a case of drastic improvement in severe insulin resistance after sleeve gastrectomy.
- To illustrate the rapid impact of sleeve gastrectomy on insulin sensitivity.
Main Methods:
- A case report of a morbidly obese patient with type 2 diabetes and severe insulin resistance.
- Utilized the Homeostasis Model Assessment of insulin resistance (HOMA-IR) to quantify insulin resistance.
- Documented changes in insulin requirements and HOMA-IR before and after sleeve gastrectomy.
Main Results:
- The patient experienced a 76% improvement in HOMA-IR between postoperative days 1 and 14.
- Insulin therapy was discontinued on postoperative day 1.
- Significant weight loss was achieved during a 6-month pre-operative medical weight management program.
Conclusions:
- Sleeve gastrectomy can lead to rapid and substantial improvements in severe insulin resistance.
- Early postoperative assessment reveals significant metabolic benefits of sleeve gastrectomy.
- Bariatric surgery offers a potent intervention for managing insulin resistance in obese patients.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
919
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:36Carbohydrate Metabolism
15.0K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
15.0K
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K